Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1631 1633 1634 1645
This examiner grants 55% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 17932633 | Modified EC7 Cells Having Low Toxicity to Viral Production Payloads | Non-Final OA | NantBio, Inc. |
| 17767970 | CANINE DISTEMPER VIRUS HEMAGGLUTININ AND FUSION POLYPEPTIDES | Final Rejection | Mayo Foundation for Medical Education and Research |
| 17273688 | BASE EDITING FOR TREATING HUTCHINSON-GILFORD PROGERIA SYNDROME | Final Rejection | President and Fellows of Harvard College |
| 17353587 | METHODS FOR CONTROLLED ACTIVATION OR ELIMINATION OF THERAPEUTIC CELLS | Final Rejection | Board of Regents of The University of Texas System |
| 17813843 | COMPOSITIONS AND METHODS FOR DECREASING TAU EXPRESSION | Non-Final OA | Novartis AG |
| 17768591 | COMPOSITIONS AND METHODS FOR USING ALTERNATIVE SPLICING TO CONTROL SPECIFICITY OF GENE THERAPY | Final Rejection | The Johns Hopkins University |
| 18847004 | DELIVERY METHODS USING PLATELETS | Non-Final OA | Children's Hospital Medical Center |
| 18041330 | CELLULAR COMPOSITIONS AND METHODS OF TREATMENT | Non-Final OA | Mesoblast International Sárl |
| 17856187 | MODIFIED SOLUBLE VEGF RECEPTOR-1 GENES AND VECTORS FOR GENE THERAPY | Non-Final OA | ASKBIO INC. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy